Cargando…

How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018

BACKGROUND: The current carriage study was set up to reinforce surveillance during/after the PCV13-to-PCVC10 switch in Belgium. AIM: This observational study monitored carriage of Streptococcus pneumoniae (Sp) serotypes, particularly those no longer covered (3, 6A, 19A), as well as Haemophilus influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Wouters, Ine, Desmet, Stefanie, Van Heirstraeten, Liesbet, Herzog, Sereina A, Beutels, Philippe, Verhaegen, Jan, Goossens, Herman, Van Damme, Pierre, Malhotra-Kumar, Surbhi, Theeten, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014673/
https://www.ncbi.nlm.nih.gov/pubmed/32046817
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.1900303
_version_ 1783496683160600576
author Wouters, Ine
Desmet, Stefanie
Van Heirstraeten, Liesbet
Herzog, Sereina A
Beutels, Philippe
Verhaegen, Jan
Goossens, Herman
Van Damme, Pierre
Malhotra-Kumar, Surbhi
Theeten, Heidi
author_facet Wouters, Ine
Desmet, Stefanie
Van Heirstraeten, Liesbet
Herzog, Sereina A
Beutels, Philippe
Verhaegen, Jan
Goossens, Herman
Van Damme, Pierre
Malhotra-Kumar, Surbhi
Theeten, Heidi
author_sort Wouters, Ine
collection PubMed
description BACKGROUND: The current carriage study was set up to reinforce surveillance during/after the PCV13-to-PCVC10 switch in Belgium. AIM: This observational study monitored carriage of Streptococcus pneumoniae (Sp) serotypes, particularly those no longer covered (3, 6A, 19A), as well as Haemophilus influenzae (Hi), because PCV10 contains the non-typeable Hi protein D. METHODS: A total of 2,615 nasopharyngeal swabs from children (6–30 months old) attending day care were collected in three periods over 2016–2018. Children’s demographic and clinical characteristics and vaccination status were obtained through a questionnaire. Sp and Hi were identified by culture and PCR. Pneumococcal strains were tested for antimicrobial (non-)susceptibility by disc diffusion and serotyped by Quellung-reaction (Quellung-reaction and PCR for serotypes 3, 6A, 19A). RESULTS: The carriage prevalence of Sp (> 75%) remained stable over the successive periods but that of Hi increased (87.4%, 664 Hi-carriers/760 in 2016 vs 93.9%, 895/953 in 2017–2018). The proportion of non-PCV13 vaccine serotypes decreased (94.6%, 438 isolates/463 in 2016 vs 89.7%, 599/668 in 2017–2018) while that of PCV13-non-PCV10 vaccine serotypes (3 + 6A + 19A) increased (0.9%, 4 isolates/463 in 2016 vs 7.8%, 52/668 in 2017–2018), with serotype 19A most frequently identified (87.9%, 58/66 isolates). Non-susceptibility of pneumococci against any of the tested antibiotics was stable over the study period (> 44%). CONCLUSIONS: During and after the PCV13-to-PCV10 vaccine switch, the proportion of non-PCV13 serotypes decreased, mainly due to a serotype 19A carriage prevalence increase. These results complement invasive pneumococcal disease surveillance data, providing further basis for pneumococcal vaccination programme policy making.
format Online
Article
Text
id pubmed-7014673
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-70146732020-02-25 How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018 Wouters, Ine Desmet, Stefanie Van Heirstraeten, Liesbet Herzog, Sereina A Beutels, Philippe Verhaegen, Jan Goossens, Herman Van Damme, Pierre Malhotra-Kumar, Surbhi Theeten, Heidi Euro Surveill Research BACKGROUND: The current carriage study was set up to reinforce surveillance during/after the PCV13-to-PCVC10 switch in Belgium. AIM: This observational study monitored carriage of Streptococcus pneumoniae (Sp) serotypes, particularly those no longer covered (3, 6A, 19A), as well as Haemophilus influenzae (Hi), because PCV10 contains the non-typeable Hi protein D. METHODS: A total of 2,615 nasopharyngeal swabs from children (6–30 months old) attending day care were collected in three periods over 2016–2018. Children’s demographic and clinical characteristics and vaccination status were obtained through a questionnaire. Sp and Hi were identified by culture and PCR. Pneumococcal strains were tested for antimicrobial (non-)susceptibility by disc diffusion and serotyped by Quellung-reaction (Quellung-reaction and PCR for serotypes 3, 6A, 19A). RESULTS: The carriage prevalence of Sp (> 75%) remained stable over the successive periods but that of Hi increased (87.4%, 664 Hi-carriers/760 in 2016 vs 93.9%, 895/953 in 2017–2018). The proportion of non-PCV13 vaccine serotypes decreased (94.6%, 438 isolates/463 in 2016 vs 89.7%, 599/668 in 2017–2018) while that of PCV13-non-PCV10 vaccine serotypes (3 + 6A + 19A) increased (0.9%, 4 isolates/463 in 2016 vs 7.8%, 52/668 in 2017–2018), with serotype 19A most frequently identified (87.9%, 58/66 isolates). Non-susceptibility of pneumococci against any of the tested antibiotics was stable over the study period (> 44%). CONCLUSIONS: During and after the PCV13-to-PCV10 vaccine switch, the proportion of non-PCV13 serotypes decreased, mainly due to a serotype 19A carriage prevalence increase. These results complement invasive pneumococcal disease surveillance data, providing further basis for pneumococcal vaccination programme policy making. European Centre for Disease Prevention and Control (ECDC) 2020-02-06 /pmc/articles/PMC7014673/ /pubmed/32046817 http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.1900303 Text en This article is copyright of the authors or their affiliated institutions, 2020. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research
Wouters, Ine
Desmet, Stefanie
Van Heirstraeten, Liesbet
Herzog, Sereina A
Beutels, Philippe
Verhaegen, Jan
Goossens, Herman
Van Damme, Pierre
Malhotra-Kumar, Surbhi
Theeten, Heidi
How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title_full How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title_fullStr How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title_full_unstemmed How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title_short How nasopharyngeal pneumococcal carriage evolved during and after a PCV13-to-PCV10 vaccination programme switch in Belgium, 2016 to 2018
title_sort how nasopharyngeal pneumococcal carriage evolved during and after a pcv13-to-pcv10 vaccination programme switch in belgium, 2016 to 2018
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7014673/
https://www.ncbi.nlm.nih.gov/pubmed/32046817
http://dx.doi.org/10.2807/1560-7917.ES.2020.25.5.1900303
work_keys_str_mv AT woutersine hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT desmetstefanie hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT vanheirstraetenliesbet hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT herzogsereinaa hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT beutelsphilippe hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT verhaegenjan hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT goossensherman hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT vandammepierre hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT malhotrakumarsurbhi hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT theetenheidi hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018
AT hownasopharyngealpneumococcalcarriageevolvedduringandafterapcv13topcv10vaccinationprogrammeswitchinbelgium2016to2018